UNIVERSITY OF TORINO – DEPARTMENT OF ONCOLOGY Treatment of ALK- and ROS-1 translocated NSCLC Massimo Di Maio, MD Department of Oncology, University of.
Esophagus CAP protocol
The Therapeutic I mplications of EML4/ALK, ROS-1 and Other N ew Biomarkers
